問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


E-DA Hospital (在職)

Division of Hematology & Oncology

Dalin Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation (在職)

Division of Hematology & Oncology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

蘇裕傑
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇裕傑

List

13Cases

2019-12-01 - 2030-05-31

Phase III

Active
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia

  • Condition/Disease

    Essential Thrombocythemia

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
23Sites

Not yet recruiting3Sites

Recruiting20Sites

2025-01-01 - 2029-12-12

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2017-08-10 - 2025-01-09

Phase III

Completed
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

  • Test Drug

    Injection Injection

Participate Sites
12Sites

Recruiting12Sites

2017-07-18 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-04-01 - 2029-09-01

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

  • Condition/Disease

    Follicular Lymphoma

  • Test Drug

    懸液用粉劑

Participate Sites
9Sites

Recruiting9Sites

2019-07-15 - 2022-12-31

Phase III

Completed
A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide

  • Condition/Disease

    復發性頑固型多發性骨髓瘤

  • Test Drug

    Melflufen

Participate Sites
8Sites

Recruiting7Sites

2017-08-01 - 2022-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2019-01-11 - 2024-12-31

Phase II

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Zanubrutinib (BGB-3111)

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2017-07-18 - 2024-06-30

Phase III

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

  • Condition/Disease

    Acute Myeloid Leukemia with an IDH1 Mutation

  • Test Drug

    Ivosidenib (AG-120);Azacitidine

Participate Sites
8Sites

Recruiting6Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2017-08-10 - 2021-06-30

Phase III

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Nivolumab/Ipilimumab

Participate Sites
15Sites

Terminated13Sites

林振源
China Medical University Hospital-Taipei

未分科

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB